Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?

• Main Authors: Enrica Teresa Tanda, Elena Croce, Francesco Spagnolo, Lodovica Zullo, Stefano Spinaci, Carlo Genova, Giovanni Rossi
• Format: Article
• Language: English
• Published: Frontiers Media S.A. 2021-09-01
• Series: Frontiers in Oncology
• Subjects: AYA; adolescent; young adults; immunotherapy; pregnancy; fertility
• Online Access: https://www.frontiersin.org/articles/10.3389/fonc.2021.736123/full

Immunotherapy has changed the landscape of treatments for advanced disease in multiple neoplasms. More and more patients are long survivors from a metastatic disease. Most recently, the extension of indications and evidence of efficacy in early disease settings, such as the adjuvant and neoadjuvant setting in breast cancer, lung cancer, glioma, and gastric cancer, places more attention on what happens to patients who survive cancer. In particular, we evaluated what happens in young patients, a population in whom some immune-related effects are still poorly described. Immunotherapy is already a reality in early disease settings and the scientific community is lagging in describing what to expect in adolescent and young adult (AYA) patients. For instance, the impact of these therapies on female and male fertility is not clear, similarly to the interaction that may occur between these drugs and pregnancy. This review aims to highlight these little-known topics that are difficult to evaluate in ad hoc studies.